{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:06:56Z","timestamp":1790719616129,"version":"4.1.0"},"reference-count":12,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-16-RHUS-0004 (RHU TRT_cSVD) ANR-18-RHUS-0001 (RHU Booster) and ANR-22-CE17-0032 (INFLAME)"],"award-info":[{"award-number":["ANR-16-RHUS-0004 (RHU TRT_cSVD) ANR-18-RHUS-0001 (RHU Booster) and ANR-22-CE17-0032 (INFLAME)"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-16-RHUS-0004 (RHU TRT_cSVD) ANR-18-RHUS-0001 (RHU Booster) and ANR-22-CE17-0032 (INFLAME)"],"award-info":[{"award-number":["ANR-16-RHUS-0004 (RHU TRT_cSVD) ANR-18-RHUS-0001 (RHU Booster) and ANR-22-CE17-0032 (INFLAME)"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>More than 50% of large vessel occlusion (LVO) acute ischemic stroke (AIS) patients treated with endovascular therapy (EVT) remain severely disabled at 3\u2009months. We hypothesized that acute astrocytic inflammatory response may play a pivotal role in post-AIS brain changes associated with poor functional outcome. We proposed to evaluate the level of YKL-40, a glycoprotein mainly released by reactive astrocytes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and methods:<\/jats:title>\n                    <jats:p>A monocentric prospective cohort study was conducted on consecutive LVO AIS patients treated with EVT. Three blood samples (before, within 1 and 24-hour post-EVT) were collected to measure plasma YKL-40 concentrations. Functional outcome was assessed according to the modified Rankin Scale (mRS) score at 3\u2009months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Between 2016 and 2020, 120 patients were included. The plasma concentration of YKL-40 before EVT was statistically and independently associated with 3-month worse functional outcome (adjusted cOR, 1.59; 95% CI [1.05\u20132.44], p\u2009=\u20090.027) but not the two following samples 1-hour and 24-hour post-EVT. Accordingly, we found that excellent functional outcome was associated with a lower level of YKL-40 before and within 1\u2009h after EVT (p\u2009=\u20090.005 and p\u2009=\u20090.003, respectively) but not when measured 24\u2009h after EVT (p\u2009=\u20090.2).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion and conclusion:<\/jats:title>\n                    <jats:p>This study suggests that the astrocytic reaction to acute brain hypoxia, especially before recanalization, is associated with worse functional outcome. Such early biomarker of the astrocytic response in AIS may optimize individualized care in the future.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trial Registration-URL:<\/jats:title>\n                    <jats:p>http:\/\/www.clinicaltrials.gov. Unique identifier: NCT02900833.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/23969873241256813","type":"journal-article","created":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T01:15:10Z","timestamp":1717722910000},"page":"952-958","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Acute astrocytic reaction is associated with 3-month functional outcome after stroke treated with endovascular therapy"],"prefix":"10.1093","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-4998-3904","authenticated-orcid":false,"given":"Ada","family":"Boutelier","sequence":"first","affiliation":[{"name":"Cognitive Neurology Center, GHU APHP Nord, H\u00f4pital Lariboisi\u00e8re-Fernand Widal, Universit\u00e9 Paris Cit\u00e9, Paris, France 1"},{"name":"Optimisation Th\u00e9rapeutique en Neuropsychopharmacologie, Universit\u00e9 Paris Cit\u00e9, U1144 Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale (INSERM), Paris, France 2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Ollivier","sequence":"additional","affiliation":[{"name":"Optimisation Th\u00e9rapeutique en Neuropsychopharmacologie, Universit\u00e9 Paris Cit\u00e9, U1144 Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale (INSERM), Paris, France 2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikael","family":"Mazighi","sequence":"additional","affiliation":[{"name":"Optimisation Th\u00e9rapeutique en Neuropsychopharmacologie, Universit\u00e9 Paris Cit\u00e9, U1144 Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale (INSERM), Paris, France 2"},{"name":"Stroke-Link F-CRIN Research Network, Lille, France 3"},{"name":"Biological Resource Center and Department of Interventional Neuroradiology, Rothschild Foundation Hospital, Paris, France 4"},{"name":"FHU NeuroVasc, Paris, France 5"},{"name":"Department of Neurology, GHU APHP NORD, H\u00f4pital Lariboisi\u00e8re, Paris, France 6"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maeva","family":"Kyheng","sequence":"additional","affiliation":[{"name":"CHU Lille, Department of Biostatistics, Lille, France 7"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Labreuche","sequence":"additional","affiliation":[{"name":"Stroke-Link F-CRIN Research Network, Lille, France 3"},{"name":"CHU Lille, Department of Biostatistics, Lille, France 7"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nahida","family":"Brikci-Nigassa","sequence":"additional","affiliation":[{"name":"Biological Resource Center and Department of Interventional Neuroradiology, Rothschild Foundation Hospital, Paris, France 4"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mialitiana","family":"Solo Nomenjanahary","sequence":"additional","affiliation":[{"name":"Optimisation Th\u00e9rapeutique en Neuropsychopharmacologie, Universit\u00e9 Paris Cit\u00e9, U1144 Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale (INSERM), Paris, France 2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0697-2156","authenticated-orcid":false,"given":"Francois","family":"Delvoye","sequence":"additional","affiliation":[{"name":"Biological Resource Center and Department of Interventional Neuroradiology, Rothschild Foundation Hospital, Paris, France 4"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Maier","sequence":"additional","affiliation":[{"name":"Stroke-Link F-CRIN Research Network, Lille, France 3"},{"name":"Biological Resource Center and Department of Interventional Neuroradiology, Rothschild Foundation Hospital, Paris, France 4"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Paquet","sequence":"additional","affiliation":[{"name":"Cognitive Neurology Center, GHU APHP Nord, H\u00f4pital Lariboisi\u00e8re-Fernand Widal, Universit\u00e9 Paris Cit\u00e9, Paris, France 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit","family":"Ho-Tin-Noe","sequence":"additional","affiliation":[{"name":"Optimisation Th\u00e9rapeutique en Neuropsychopharmacologie, Universit\u00e9 Paris Cit\u00e9, U1144 Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale (INSERM), Paris, France 2"},{"name":"Stroke-Link F-CRIN Research Network, Lille, France 3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Philippe","family":"Desilles","sequence":"additional","affiliation":[{"name":"Optimisation Th\u00e9rapeutique en Neuropsychopharmacologie, Universit\u00e9 Paris Cit\u00e9, U1144 Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale (INSERM), Paris, France 2"},{"name":"Stroke-Link F-CRIN Research Network, Lille, France 3"},{"name":"Biological Resource Center and Department of Interventional Neuroradiology, Rothschild Foundation Hospital, Paris, France 4"},{"name":"FHU NeuroVasc, Paris, France 5"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the NeutroStroke Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,12,1]]},"reference":[{"key":"2026012113103810000_bibr1-23969873241256813","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1016\/S0140-6736(16)00163-X","article-title":"Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials","volume":"387","author":"Goyal","year":"2016","journal-title":"Lancet"},{"key":"2026012113103810000_bibr2-23969873241256813","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/S1474-4422(19)30078-X","article-title":"Global brain inflammation in stroke","volume":"18","author":"Shi","year":"2019","journal-title":"Lancet Neurol"},{"key":"2026012113103810000_bibr3-23969873241256813","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1111\/jnc.15824","article-title":"Astrocytic chitinase-3-like protein 1 in neurological diseases: potential roles and future perspectives","volume":"165","author":"Li","year":"2023","journal-title":"J Neurochem"},{"key":"2026012113103810000_bibr4-23969873241256813","first-page":"120","article-title":"Elevation in circulating YKL-40 concentration in patients with cerebrovascular disease","volume":"14","author":"Xu","year":"2014","journal-title":"Bosn J Basic Med Sci"},{"key":"2026012113103810000_bibr5-23969873241256813","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0051722","article-title":"Serum YKL-40 levels correlate with infarct volume, stroke severity, and functional outcome in acute ischemic stroke patients","volume":"7","author":"Park","year":"2012","journal-title":"PLoS One"},{"key":"2026012113103810000_bibr6-23969873241256813","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000007859","article-title":"Neutrophil count predicts poor outcome despite recanalization after endovascular therapy","volume":"93","author":"Boisseau","year":"2019","journal-title":"Neurology"},{"key":"2026012113103810000_bibr7-23969873241256813","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1161\/STROKEAHA.111.634089","article-title":"The use of blood biomarkers to predict poor outcome after acute transient ischemic attack or ischemic stroke","volume":"43","author":"Whiteley","year":"2012","journal-title":"Stroke"},{"key":"2026012113103810000_bibr8-23969873241256813","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1136\/jnis-2022-020020","article-title":"Neutrophil activation in patients treated with endovascular therapy is associated with unfavorable outcomes and mitigated by intravenous thrombolysis","volume":"16","author":"Ma\u00efer","year":"2024","journal-title":"J Neurointerv Surg"},{"key":"2026012113103810000_bibr9-23969873241256813","doi-asserted-by":"crossref","first-page":"107394","DOI":"10.1016\/j.pharmthera.2019.107394","article-title":"Roles of chitinase 3-like 1 in the development of cancer, neurodegenerative diseases, and inflammatory diseases","volume":"203","author":"Yeo","year":"2019","journal-title":"Pharmacol Ther"},{"key":"2026012113103810000_bibr10-23969873241256813","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1742-2094-7-34","article-title":"In vivo CHI3L1 (YKL-40) expression in astrocytes in acute and chronic neurological diseases","volume":"7","author":"Bonneh-Barkay","year":"2010","journal-title":"J Neuroinflammation"},{"key":"2026012113103810000_bibr11-23969873241256813","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s12974-017-0893-7","article-title":"YKL-40 (Chitinase 3-like I) is expressed in a subset of astrocytes in Alzheimer\u2019s disease and other tauopathies","volume":"14","author":"Querol-Vilaseca","year":"2017","journal-title":"J Neuroinflammation"},{"key":"2026012113103810000_bibr12-23969873241256813","doi-asserted-by":"crossref","first-page":"39893","DOI":"10.1074\/jbc.M111.257451","article-title":"A complex of nuclear factor I-X3 and STAT3 regulates astrocyte and glioma migration through the secreted glycoprotein YKL-40","volume":"286","author":"Singh","year":"2011","journal-title":"J Biol Chem"}],"container-title":["European Stroke Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/23969873241256813","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/23969873241256813","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/esj\/article-pdf\/9\/4\/952\/64653279\/23969873241256813.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/esj\/article-pdf\/9\/4\/952\/64653279\/23969873241256813.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T18:11:56Z","timestamp":1769019116000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/esj\/article\/9\/4\/952\/8269080"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,1]]},"references-count":12,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,12,1]]}},"URL":"https:\/\/doi.org\/10.1177\/23969873241256813","relation":{},"ISSN":["2396-9873","2396-9881"],"issn-type":[{"value":"2396-9873","type":"print"},{"value":"2396-9881","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,12,1]]},"published":{"date-parts":[[2024,12,1]]}}}